Pfizer has retracted a 2009 Journal of Clinical Oncology study purporting to show a benefit of their experimental drug for lung cancer figitumumab after discovering that its clinical lead on the project had done analyses improperly.
Laurence Klotz, a prominent urologist at the University of Toronto who studies the prostate specific antigen (PSA), has corrected a paper after reusing his own words from an earlier review.
Here’s the correction, from the Journal of Clinical Oncology (JCO): Continue reading Duplication earns highly cited prostate cancer researcher a correction in JCO
The Journal of Clinical Oncology has issued an expression of concern about a 2003 article by a group of researchers in Spain who appear to have had recurrent problems with images.
The paper has been cited 56 times, according to Thomson Scientific’s Web of Knowledge. Here’s the notice:
It has been brought to our attention, regarding Figure 1, Part A, that similarity exists between bands 3, 4, and 5 of the top row and bands 1, 2, and 3 of the bottom row, including the presence of artifacts, in the April 15, 2003 article by [Jose] RomanGomez et al, entitled, “Cadherin-13, a Mediator of Calcium Dependent Cell-Cell Adhesion, Is Silenced by Methylation in Chronic Myeloid Leukemia and Correlates With Pretreatment Risk Proﬁle and Cytogenetic Response to Interferon Alfa” (J Clin Oncol 21:1472-1479, 2003). This similarity has raised concerns about whether these rows represent independent data. We alerted the corresponding author, Dr. Roman-Gomez, of this concern, and he has repeated the experiment shown in the original Figure 1, with the results below. Although the results of the ﬁgure appear to be unchanged, we wish to inform the readers of this issue, so that they may make their own independent assessment.
Anil Potti can add two corrections to his less-and-less impressive publication record. The mega-corrections — part of what we are close to being ready to call a trend in errata notices — in the Journal of Clinical Oncology (JCO) are, however, quite impressive, each with at least a dozen points.
One of the corrections, for a paper cited 15 times, according to Thomson Scientific’s Web of Knowledge, basically removes all references to chemotherapy sensitivity: Continue reading Two mega-corrections for Anil Potti in the Journal of Clinical Oncology
“An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer” by Holly K. Dressman, Andrew Berchuck, Gina Chan, Jun Zhai, Andrea Bild, Robyn Sayer, Janiel Cragun, Jennifer Clarke, Regina S. Whitaker, LiHua Li, Jonathan Gray, Jeffrey Marks, Geoffrey S. Ginsburg, Anil Potti, Mike West, Joseph R. Nevins, and Johnathan M. Lancaster (J Clin Oncol 25:517-525, 2007)
The majority of the authors wish to retract this article because Continue reading Anil Potti and colleagues retract ninth paper, this one in JCO
The Journal of Clinical Oncology (JCO) has retracted a November 2011 editorial by a group of French cancer researchers, including David Khayat, the former head of that country’s National Cancer Institute, over what appears to be fairly extensive plagiarism.
Here’s the notice for the article, “Lymphocyte Infiltration in Breast Cancer: A Key Prognostic Factor That Should Not Be Ignored:” Continue reading JCO retracts article from major French cancer group over apparent plagiarism
The Retraction Watch category for “lack of IRB approval” as a reason for retraction — a subject we covered in our most recent Lab Times column — is growing. First there were the 90-odd retractions by Joachim Boldt, then three by Australian researchers studying Aussie-rules football players. Now, we learn that the Journal of Clinical Oncology has retracted a paper over concerns that the authors failed to obtain ethical approval to conduct their study.
The 2010 publication, by researchers at Saitama Medical University in Japan, reported on an analysis of 314 lymphoma patients being treated with chemotherapy — some, and perhaps none, of whom knew they were being studied.
In our very first post, we noted the case of Anil Potti,
a Duke researcher who posed as a Rhodes Scholar and appears to have invented key statistical analyses in a study of how breast cancer responds to chemotherapy[.The case] has sent ripples of angst through the cancer community. Potti’s antics prompted editors of The Lancet Oncology to issue an “expression of concern” — a Britishism that might be better expressed as “Holy Shit!” — about the validity of a 2007 paper in their journal by Potti and others.
There hasn’t been any further movement on The Lancet Oncology study, as far as we know, but on Friday the Raleigh News & Observer reported that one of Potti’s co-authors on a 2007 Journal of Clinical Oncology (JCO) paper had requested a retraction: Continue reading A retraction in the Potti case?